You are here: Industry Insights > Dovato

News List

ViiV posts positive long-term data for two-drug HIV regimen Dovato pharmatimes
October 14, 2020
GlaxoSmithKline subsidiary ViiV Healthcare has reported new data for its two-drug HIV regimen Dovato, with hopes that the long-term data could encourage clinicians to switch from other triple regimen therapies.
ViiV Healthcare gets FDA expanded approval for HIV-1 drug Dovato pharmaceutical-business-review
August 11, 2020
Specialist HIV company ViiV Healthcare has secured approval from the US Food and Drug Administration (FDA) for its Dovato (dolutegravir/lamivudine) as a complete regimen to treat HIV-1 infection.
ViiV Healthcare secures Japanese approval for Dovato to treat HIV-1 infection pharmaceutical-business-review
January 19, 2020
Specialist HIV company ViiV Healthcare has secured Japanese approval for Dovato (dolutegravir 50mg/lamivudine 300mg) two-drug regimen to treat of HIV-1 infection.
HIV treatment Dovato (dolutegravir/lamivudine) approved in Japan europeanpharmaceuticalreview
January 16, 2020
The Japanese Ministry of Health, Labour and Welfare (MHLW) has granted marketing approval for Dovato, a treatment for HIV-1 infection.
FDA Approves Dovato (dolutegravir/lamivudine) for HIV-1 Infection drugs
April 17, 2019
FDA Approves Dovato (dolutegravir/lamivudine) for HIV-1 Infection.
ViiV’s two-drug regimen Dovato gets FDA approval for HIV-1 pharmaceutical-technology
April 11, 2019
ViiV’s two-drug regimen Dovato gets FDA approval for HIV-1.
FDA Approves Two-Drug HIV Therapy for Previously Untreated Patients americanpharmaceuticalreview
April 11, 2019
FDA Approves Two-Drug HIV Therapy for Previously Untreated Patients.
GSK's Dovato chalks up first 2-drug regimen nod for new HIV patients fiercepharma
April 10, 2019
In a landmark win for GlaxoSmithKline’s ViiV Healthcare and its ambition to reduce the number of medications HIV patients are taking……
ViiV Healthcare's Dovato approved in US as first two-drug single-tablet regimen for patients with treatment-naïve HIV firstwordpharma
April 09, 2019
The FDA on Monday announced the approval of ViiV Healthcare's Dovato (dolutegravir/lamivudine) for ^